Renal sympathetic denervation for the treatment of hypertensive heart
disease with systolic heart failure

doi:10.11958/20150136

Tianjin Med J ›› 2016, Vol. 44 ›› Issue (2): 234-236.doi: 10.11958/20150136

Previous Articles Next Articles

Renal sympathetic denervation for the treatment of hypertensive heart disease with systolic heart failure

XIA Dasheng, LU Chengzhi, WANG Li

Department of Cardiology of Tianjin First Center Hospital, Tianjin 300192,China

Received:2015-08-31 Revised:2015-10-29 Published:2016-02-15 Online:2016-02-15

XIA Dasheng, LU Chengzhi, WANG Li. Renal sympathetic denervation for the treatment of hypertensive heart disease with systolic heart failure[J]. Tianjin Med J, 2016, 44(2): 234-236.

Abstract

Abstract: Objective To evaluate the effectiveness of renal sympathetic denervation (RDN) for hypertensive heart dis⁃ ease combined with systolic heart failure. Methods Two patients (mean age 35 years) with hypertensive heart disease combined with systolic heart failure on maximal tolerated heart failure therapy underwent bilateral renal denervation. Echocardiography, the six minute walk distance, renal function, glycosylated hemoglobin and NT-proBNP were assessed at baseline and 1 year after renal denervation. Results Renal artery angiography showed that no stenosis and dissection. After 1 year follow up, the left ventricular ejection fraction (LVEF), six minute walk distance and NT- proBNP were significantly improved, and the size of left ventricular decreased. Conclusion RDN is effective and feasible for the treatment in patients with hypertensive heart disease and systolic heart failure.

Key words: renal sympathetic denervation, systolic heart failure, hypertension

[1]	JIA Wei, TIAN Zhi. Correlation between Furin promoter methylation levels and blood pressure of non-diabetic population in a community [J]. Tianjin Medical Journal, 2025, 53(9): 987-992.
[2]	DU Xintao, SUO Ying, ZHAO Xiaoyun. Research progress on the bidirectional relationship between sleep-related breathing disorders and pulmonary hypertension [J]. Tianjin Medical Journal, 2025, 53(8): 889-896.
[3]	WU Bin, YANG Zigeng, JIN Ling, ZHANG Jing, WEI Hongmei, CAI Bingbing, WEI Yuying. Effect of miRNA-381-3p/MuRF1 axis on cardiopulmonary injury in mice with hypoxic pulmonary hypertension [J]. Tianjin Medical Journal, 2025, 53(6): 571-577.
[4]	WU Bin, YANG Zigeng, ZHANG Jing, LI Shuhong, YU Feng, WANG Jiawei, LI Cailing. Effect of naringenin on right ventricular remodeling induced by hypoxic pulmonary hypertension [J]. Tianjin Medical Journal, 2025, 53(2): 129-134.
[5]	WANG Lyu, LU Hong. The evaluate value of combined plasma ET-1 and NO levels in maternal and infant outcomes of patients with hypertensive disorders in pregnancy [J]. Tianjin Medical Journal, 2025, 53(11): 1185-1190.
[6]	WU Caixin, YAN Yan, DENG Yuanlin, DU Yamin, YANG Zhenwen, PAN Qing, YANG Fan. The value of cardiac magnetic resonance in evaluating severe pulmonary hypertension associated with connective tissue disease [J]. Tianjin Medical Journal, 2024, 52(7): 691-694.
[7]	WANG Hui, PAN Qing, WANG Zhouming, ZHANG Na, YANG Zhenwen, WEI Wei. Analysis of clinical features of mixed connective tissue disease associated with pulmonary arterial hypertension [J]. Tianjin Medical Journal, 2024, 52(7): 701-703.
[8]	LI Yong, SU Yakun, ZHANG Hongbo, LI Yuan, LI Zhanhu, YAN Xiaoju. Clinical significance of serum asprosin level in patients with early renal damage of essential hypertension [J]. Tianjin Medical Journal, 2024, 52(6): 609-613.
[9]	ZHENG Kangpeng, TANG Xinguo, XU Qi, FAN Yuting, LIANG Bo, FU Xiaowei, FANG Lu. Nomogram construction and validation for predicting the possibility successful implementation of radical surgery in gallbladder cancer patients [J]. Tianjin Medical Journal, 2024, 52(5): 536-540.
[10]	ZHANG Liran, ZHAO Yanhua. The predictive value of MP hypertension monitoring system combined with PLGF and PI for preeclampsia [J]. Tianjin Medical Journal, 2024, 52(3): 306-310.
[11]	CAO Junyang, MA Chunxing, LIU Zhina. Predictive value of vitamin and folic acid levels in gestational diabetes mellitus complicated by preeclampsia [J]. Tianjin Medical Journal, 2024, 52(12): 1278-1282.
[12]	QIN Chundi, MA Wen, LI Yuan, ZHU Yaquan, LI Yu, ZOU Lin, ZHANG Xin. Butyrate reduces blood pressure in hypertensive rats by activating the G protein-coupled receptor 41/43 pathway [J]. Tianjin Medical Journal, 2023, 51(9): 972-976.
[13]	ZHANG Zhaoxia, NAN Xingmei, LI Zhanqiang, LU Dianxiang. Research progress on the role of potassium channels and drug intervention in hypoxic pulmonary hypertension [J]. Tianjin Medical Journal, 2023, 51(8): 892-896.
[14]	ZHANG Wenjing, WEN Dehui, ZHENG Yingjuan, LI Chaoxi, NIU Yajun, MIAO Qing. The study of QAS combined with QIMT technology on carotid atherosclerosis in patients with normal high blood pressure [J]. Tianjin Medical Journal, 2023, 51(6): 662-667.
[15]	ZHENG Yue, MA Yunting, ZHAO Xiaoying, ZHAO Xinxiang. Correlation between homocysteine and left ventricular myocardial fibrosis in hypertensive patients [J]. Tianjin Medical Journal, 2023, 51(4): 395-399.

Renal sympathetic denervation for the treatment of hypertensive heart disease with systolic heart failure

Cite this article

PDF (PC)

Knowledge

Abstract

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments